Plasminogen Activator Inhibitor-1 in Acute Myeloid Leukemia: Is It Useful in Predicting Response to Induction Remission Therapy?

Haider Hasan Jaleel Al-Shammari; Israa Al-Bayaa; Haithem Ahmed Al-Rubaie

doi:10.3889/oamjms.2022.10370

Authors

Haider Hasan Jaleel Al-Shammari Department of Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq
Israa Al-Bayaa Department of Pathology, College of Medicine, University of Kerbala, Karbala, Iraq https://orcid.org/0000-0001-5512-9539
Haithem Ahmed Al-Rubaie Department of Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq

DOI:

https://doi.org/10.3889/oamjms.2022.10370

Keywords:

Acute myeloblastic leukemia, Plasminogen activator inhibitor-1, Remission induction

Abstract

BACKGROUND: Coagulation and fibrinolytic abnormalities are common in patients with acute myeloblastic leukemia (AML). Plasminogen activator inhibitor (PAI) activity is believed to be elevated during the initial diagnosis and relapse of AML patients.

AIM: This study aimed to evaluate the levels of plasma PAI-1 activity in AML patients before and after remission induction.

METHODS: Thirty AML patients and 20 healthy volunteers were included in this study. The patients were classified according to AML-FAB subtypes. All patients received 7+3 induction chemotherapy. They were evaluated for complete remission after induction chemotherapy and followed up for 6 months.

RESULTS: PAI-1 activity was measured by ELISA immunoassay. PAI-1 activity was significantly higher in AML patients than the control group (P=0.016), whereas there was insignificant difference among patients in various AML subgroups (P>0.05). Before and after treatment, there was a significant difference in PAI-1 activity between patients with active disease and those at remission (P= 0.023 and <0.0001, respectively).

CONCLUSION: High PAI-1 activity in AML patients is found to be associated with poor response to treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. https://doi.org10.1182/blood-2016-03-643544 PMid:27069254 DOI: https://doi.org/10.1182/blood-2016-03-643544

Dicke C, Amirkhosravi A, Spath B, Jiménez-Alcázar M, Fuchs T, Davila M, et al. Tissue factor dependent and independent pathways of systemic coagulation activation in acute myeloid leukemia: A single center cohort study. Exp Hematol Oncol. 2015;4:22. https://doi.org/10.1186/s40164-015-0018-x PMid:26251762 DOI: https://doi.org/10.1186/s40164-015-0018-x

Pöllanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res. 1991;57:273-328. http://doi.org/10.1016/s0065-230x(08)61002-7 PMid:1950706 DOI: https://doi.org/10.1016/S0065-230X(08)61002-7

Andreasen P, Egelund R, Petersen H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000;57(1):25-40. https://doi.org/10.1007/s000180050497 PMid:10949579 DOI: https://doi.org/10.1007/s000180050497

Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005;93(4):647-54. https://doi.org/10.1160/TH04-12-0842 PMid:15841308 DOI: https://doi.org/10.1160/TH04-12-0842

Bai H, Nangia S, Parmer RJ. The plasminogen activation system and the regulation of catecholaminergic function. Biomed Res Int. 2012;2012:721657. https://doi.org/10.1155/2012/721657 PMid:23097598 DOI: https://doi.org/10.1155/2012/721657

De Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24(1):13-39. https://doi.org/10.1002/med.10054 PMid:14595671 DOI: https://doi.org/10.1002/med.10054

Li S, Wei X, He J, Tian X, Yuan S, Sun L. Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother. 2018;105:83-94. https://doi.org/10.1016/j.biopha.2018.05.119 PMid:29852393 DOI: https://doi.org/10.1016/j.biopha.2018.05.119

Nadir Y, Katz T, Sarig G, Hoffman R, Oliven A, Rowe JM, et al. Hemostatic balance on the surface of leukemic cells: The role of tissue factor and urokinase plasminogen activator receptor. Haematologica. 2005;90(11):1549-56. PMid:16266903

Rubio-Jurado B, Tello-González A, Bustamante-Chávez L, De la Peña A, Riebeling-Navarro C, Nava-Zavala AH. Circulating levels of urokinase-type plasminogen activator receptor and d-dimer in patients with hematological malignancies. Clin Lymphoma Myeloma Leuk. 2015;15(10):621-6. https://doi.org/10.1016/j.clml.2015.07.632 PMid:26423703 DOI: https://doi.org/10.1016/j.clml.2015.07.632

Raosoft Sample Size Calculator. Available from: https://www.raosoft.com/samplesize.html [Last accessed on 2018 Jan 15].

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47. https://doi.org/10.1182/blood-2016-08-733196 PMid:27895058 DOI: https://doi.org/10.1182/blood-2016-08-733196

Lee JH, Lee KH, Lee JH, Kim S, Seol M, Park CJ, et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adult conditioned with busulfan and cyclophosphamide. Br J Haematol. 2002;118(4):1087-94. https://doi.org/10.1046/j.1365-2141.2002.03748.x PMid:12199790 DOI: https://doi.org/10.1046/j.1365-2141.2002.03748.x

Holmgren L, O’Reilly MS, Folkman J. Dormancy of micro metastases, balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med J. 1995;1(2):149-53. https://doi.org/10.1038/nm0295-149 PMid:7585012 DOI: https://doi.org/10.1038/nm0295-149

Yilmaz M, Dagdas S, Aki SZ, Guler N, Akoz AG, Erdin Z, et al. The relation between plasminogen activator inhibitor activity and disease activation in acute myeloblastic leukaemia patients. Clin Lab Haematol. 2006;28(5):313-6. https://doi.org/10.1111/j.1365-2257.2006.00820.x PMid:16999721 DOI: https://doi.org/10.1111/j.1365-2257.2006.00820.x

Atfy M, Eissa M, Salah HE, El Shabrawy DA. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. Med Oncol. 2012;29(3):2063-9. https://doi.org/10.1007/s12032-011-9993-x PMid:21638078 DOI: https://doi.org/10.1007/s12032-011-9993-x

Erkut N, Menteşe A, Özbaş HM, Ermantaş N, Sümer A, Örem A, et al. The prognostic significance of soluble urokinase plasminogen activator receptor in acute myeloid leukemia. Turk J Hematol. 2016;33(2):135-40. https://doi.org/10.4274/tjh.2014.0405 PMid:26376588 DOI: https://doi.org/10.4274/tjh.2014.0405